News from Nektar Therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

20 Apr, 2017, 09:10 ET Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an analyst and investor event with clinical investigators on Saturday, June 3,...


04 Apr, 2017, 09:00 ET Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced five preclinical data presentations for its immuno-oncology programs made at the American...


27 Mar, 2017, 09:00 ET Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders

Nektar Therapeutics (NASDAQ: NKTR) today announced that it has begun dosing in a Phase 1 clinical study evaluating NKTR-358, the company's new...


20 Mar, 2017, 07:30 ET NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain

Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid...


02 Mar, 2017, 19:01 ET Nektar to Webcast Presentation at Cowen and Company's 37th Annual Health Care Conference in Boston

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Cowen and Company 37th Annual...


01 Mar, 2017, 16:30 ET Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced five data presentations will be delivered at the upcoming American Association for Cancer...


01 Mar, 2017, 16:10 ET Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2016. Cash and...


22 Feb, 2017, 17:07 ET Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2016 on Wednesday, March 1, 2017, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2016, on Wednesday, March...


18 Feb, 2017, 19:24 ET Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium

Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in...


05 Jan, 2017, 09:00 ET Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 35th Annual...


14 Nov, 2016, 09:00 ET Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the Jefferies 2016 London...


09 Nov, 2016, 14:30 ET Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, were presented...


03 Nov, 2016, 16:10 ET Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2016. Cash and investments in...


28 Oct, 2016, 08:15 ET Nektar to Hold Investor & Analyst Event at 2016 Society for Immunotherapy of Cancer Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event at the upcoming Society for Immunotherapy of...


28 Oct, 2016, 08:00 ET Nektar Therapeutics Announces Upcoming Presentations at the 2016 Society for Immunotherapy of Cancer Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced five data presentations will be delivered at the upcoming Society for Immunotherapy of Cancer...


27 Oct, 2016, 16:15 ET Nektar to Announce Financial Results for the Third Quarter 2016 on Thursday, November 3, 2016, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2016, on Thursday, November 3,...


19 Oct, 2016, 00:52 ET Nektar Therapeutics Prices Public Offering of Shares of Common Stock

Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") today announced the pricing of its previously announced underwritten public offering of $175.5...


17 Oct, 2016, 16:01 ET Nektar Therapeutics Announces Public Offering of Shares of Common Stock

Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") today announced that it has commenced an underwritten public offering of $175 million of shares of...


27 Sep, 2016, 07:45 ET Nektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb

 Nektar Therapeutics (Nasdaq: NKTR) announced that it will host a conference call to discuss today's announcement of the new clinical...


03 Aug, 2016, 16:15 ET Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2016. Cash and investments in...


27 Jul, 2016, 17:15 ET Nektar to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2016, on Wednesday,...


06 Jun, 2016, 14:00 ET Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity

Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being...


02 Jun, 2016, 18:30 ET Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City

 Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies...


02 Jun, 2016, 16:30 ET Nektar Therapeutics Announces Executive Management Promotions

 Nektar Therapeutics (NASDAQ: NKTR) announced today that John Nicholson has been named Senior Vice President & Chief Operating Officer and...


03 May, 2016, 16:05 ET Nektar Therapeutics Reports Financial Results for the First Quarter of 2016

 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2016. Cash and investments in...